![]() Studies show AMD patients, many of them elderly, often miss or delay monthly appointments because of illness, transportation problems, or just the unpredictable nature of life. Making treatment less burdensome is not just a matter of comfort or convenience. Other innovations, including longer-acting drugs and even gene therapy, are also in the research pipeline. ![]() Researchers hope the results will lead to Food and Drug Administration approval in about three years. The port, being developed by Lucentis’ maker, Genentech, will soon begin the final phase of clinical testing at sites across the country. In This Family Nobody Fights Alone Macular Degeneration Awareness Clock By Scttletitia 34.16 MACULAR DEGENERATION Warrior Its Not For The Weak Clock By largellie 34. “But it’s also exciting that there’s new medical technology that has had great success.” “It’s exciting that I don’t have to get shots every month,” said Roth, an online retailer and grandmother. Twice a year, the tiny “port” will be refilled with a concentrated version of Lucentis. An experimental drug delivery device, about the size of a grain of rice, was surgically implanted in her eye at Wills Eye Hospital. Lessening that drawback has been a goal of researchers ever since the drug debuted 12 years ago - the first treatment to slow age-related macular degeneration (AMD).Įarlier this month, Roth, 59, of Cherry Hill, opted for a wave of the future. The vision in her left eye went from “a big black blotchy circle” to nearly normal thanks to a drug that stopped the growth of abnormal blood vessels.īut the medication, Lucentis, has to be injected into the eyeball every month by an ophthalmologist. time on your alarm clock without squinting and fumbling for your glasses. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |